AI English summary of an SEC filing — figures as filed
Agilent Technologies AAgilent said in a press release dated November 25, 2024 that it had reorganized its operating structure into three businesses: life sciences and diagnostics markets, applied markets, and Agilent CrossLab. The company said each business constitutes a new reportable segment.
Key points
AI summaryAgilent said in a press release dated November 25, 2024 that it had reorganized its operating structure into three businesses: life sciences and diagnostics markets, applied markets, and Agilent CrossLab. The company said each business constitutes a new reportable segment.
The company said its financial statements will reflect the new reporting structure beginning with the quarter ended January 31, 2025, with prior periods recast accordingly. It said the 8-K was furnished to present selected unaudited historical financial information under the new segments.
Agilent disclosed that the Agilent CrossLab segment reported FY24 full-year revenue of $2,747 million, income from operations of $925 million, and an operating margin of 33.7%. FY23 revenue was $2,656 million, income from operations was $839 million, and operating margin was 31.6%.
Agilent disclosed that the life sciences and diagnostics markets segment reported FY24 full-year revenue of $2,466 million, income from operations of $484 million, and an operating margin of 19.6%. FY23 revenue was $2,780 million, income from operations was $673 million, and operating margin was 24.2%.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Reorganized into Three Business Segments
Agilent said in a press release dated November 25, 2024 that it had reorganized its operating structure into three businesses: life sciences and diagnostics markets, applied markets, and Agilent CrossLab. The company said each business constitutes a new reportable segment.
Source · Based on the filing body and exhibits
New Reporting Structure Effective from the Quarter Ended January 31, 2025
The company said its financial statements will reflect the new reporting structure beginning with the quarter ended January 31, 2025, with prior periods recast accordingly. It said the 8-K was furnished to present selected unaudited historical financial information under the new segments.
Source · Based on the filing body and exhibits
CrossLab Segment FY24 Revenue and Operating Income
Agilent disclosed that the Agilent CrossLab segment reported FY24 full-year revenue of $2,747 million, income from operations of $925 million, and an operating margin of 33.7%. FY23 revenue was $2,656 million, income from operations was $839 million, and operating margin was 31.6%.
Source · Based on the filing body and exhibits
Life Sciences and Diagnostics Markets Segment FY24 Revenue and Operating Income
Agilent disclosed that the life sciences and diagnostics markets segment reported FY24 full-year revenue of $2,466 million, income from operations of $484 million, and an operating margin of 19.6%. FY23 revenue was $2,780 million, income from operations was $673 million, and operating margin was 24.2%.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…